MNKD - MannKind Corp.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The Companys lead product candidate, AFREZZA (insulin human) Inhalation Powder, is insulin that has completed Phase III clinical trials. AFREZZA utilizes its Technosphere formulation technology, which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. With AFREZZA, the Company loads recombinant human insulin onto the Technosphere particles, however, this technology is not limited to insulin delivery. In March 2009, the Company submitted a new drug application (NDA) to the United Stated Food and Drug Administration (FDA) for AFREZZA. In June 2009, it acquired a quantity of bulk insulin from Pfizer Manufacturing Frankfurt GmbH, a subsidiary of Pfizer Inc.